Trending NewsTrending NewsNASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis $16.42 +0.36 (+2.24%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$16.41 -0.01 (-0.06%) As of 08/8/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARWR alerts:Sign Up Key Stats Today's Range$15.01▼$16.4850-Day Range$14.71▼$18.8852-Week Range$9.57▼$27.34Volume2.81 million shsAverage Volume2.03 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice Target$43.14Consensus RatingModerate Buy Company Overview Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. Read More Arrowhead Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreARWR MarketRank™: Arrowhead Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 225th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arrowhead Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($3.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioArrowhead Pharmaceuticals has a PEG Ratio of 23.18. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 10.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.99% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently decreased by 1.58%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.55 Percentage of Shares Shorted8.99% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently decreased by 1.58%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment0.24 News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Arrowhead Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest14 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows2 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arrowhead Pharmaceuticals' insider trading history. Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Stock News HeadlinesArrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call TranscriptAugust 8 at 9:00 PM | seekingalpha.comARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS…August 8 at 8:31 PM | finance.yahoo.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.August 9 at 2:00 AM | The Oxford Club (Ad)Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter ResultsAugust 8 at 5:28 AM | finance.yahoo.comArrowhead (ARWR) Q3 Revenue Drops 41%August 7 at 5:37 PM | fool.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $43.71 Consensus Price Target from BrokeragesAugust 2, 2025 | americanbankingnews.comArrowhead unit sells rights for plozasiran to Sanofi in Greater ChinaAugust 1, 2025 | msn.comArrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough DealJuly 31, 2025 | finance.yahoo.comSee More Headlines ARWR Stock Analysis - Frequently Asked Questions How have ARWR shares performed this year? Arrowhead Pharmaceuticals' stock was trading at $18.80 on January 1st, 2025. Since then, ARWR shares have decreased by 12.7% and is now trading at $16.42. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its quarterly earnings data on Thursday, August, 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by $0.32. The biotechnology company earned $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. Read the conference call transcript. Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' top institutional shareholders include Geode Capital Management LLC (2.16%), Aberdeen Group plc (0.70%), Bank of New York Mellon Corp (0.59%) and Privium Fund Management B.V. (0.44%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, William D Waddill, Adeoye Y Olukotun, Hongbo Lu and Victoria Vakiener. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX). Company Calendar Last Earnings8/07/2025Today8/09/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARWR CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees400Year FoundedN/APrice Target and Rating Average Price Target for Arrowhead Pharmaceuticals$43.14 High Price Target$80.00 Low Price Target$17.00 Potential Upside/Downside+162.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth23.18Net Income-$599.49 million Net MarginsN/A Pretax Margin-27.93% Return on Equity-47.81% Return on Assets-11.95% Debt Debt-to-Equity Ratio0.31 Current Ratio5.15 Quick Ratio5.15 Sales & Book Value Annual Sales$3.55 million Price / Sales638.76 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book10.66Miscellaneous Outstanding Shares138,100,000Free Float132,162,000Market Cap$2.27 billion OptionableOptionable Beta0.94 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ARWR) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.